Strict Standards: Non-static method JSite::getMenu() should not be called statically, assuming $this from incompatible context in /home/aidsdrug/public_html/ on line 90

Strict Standards: Non-static method JApplication::getMenu() should not be called statically, assuming $this from incompatible context in /home/aidsdrug/public_html/ on line 536

Strict Standards: Only variables should be assigned by reference in /home/aidsdrug/public_html/ on line 90
Home - PrEP UK

Advancing Access to PrEP Treatments In The UK


Do you want more information about PrEP? If you have not been having luck with your local health department or an infectious disease specialist, then this website is a response to the challenges you're facing.

PrEP is a powerful new tool in the worldwide public health campaign to prevent new HIV infections. Years of rigorous clinical trials have proven that the single pill daily regimen can prevent HIV negative individuals from contracting HIV from positive individuals. Many patients and providers understandably have concerns about the unintended consequences of administering antiretroviral drugs to healthy people.

Decades of research has shown that millions of men, women and transgender people of all sexual orientations do not consistently use condoms during vaginal or anal sex. Many HIV positive individuals are unaware that they have the virus, so assuming that everyone knows their status is a faulty assumption, and shaming people who do not use condoms isn't an effective public health strategy.

During the initial outbreak of HIV in the early 1980's, no treatments existed, so an HIV diagnosis was almost always perceived as a terminal illness. Condoms were the only way sexually active people could protect themselves, and a lot of them were fortunately able to change their behaviors leading to a drop in new infections during the late 1980's and early 1990's. Since highly-active antiretroviral therapy has transformed HIV into a manageable chronic illness rather than a death sentence, infection rates have been back on the rise, especially in minority communities.

Perhaps the biggest concern raised by PrEP critics is an ethical one: Given that millions of people living with HIV lack access to antiretrovirals, should we be giving them to healthy people? This is a very legitimate question. Issues surrounding affordability and access are complex and being addressed by governments, nonprofits and pharmaceutical companies. In the meantime, however, PrEP has been scientifically proven to reduce new HIV infections, so it would be unethical to withhold it from the general public. Ending the worldwide AIDS pandemic requires a two-fold strategy of making sure all HIV positive people have access to medications and uninfected individuals stay uninfected. PrEP will hopefully propel us one step closer to an AIDS-free generation.